ArticleDiscover oncology2026
A differential single-cell transcriptome atlas of left-sided and right-sided colorectal cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Left-sided colorectal cancer (LCRC) and right-sided colorectal cancer (RCRC) show marked differences in prognosis and therapeutic response, yet the underlying molecular mechanisms remain poorly understood. We hypothesize that these clinical differences reflect distinct cell-type-specific transcriptional programs and microenvironmental interactions that can be resolved at single-cell resolution. To test this hypothesis, this study analyzed single-cell transcriptomic data from 16 colorectal cancer (CRC) patients (8 LCRC and 8 RCRC), revealing molecular differences between LCRC and RCRC in tumor cells, T cells, B cells, myeloid cells, fibroblasts, and endothelial cells, and constructing a differential atlas of LCRC versus RCRC. Significant molecular and cellular differences were observed between LCRC and RCRC. MTRNR2L8 was markedly upregulated in RCRC tumor cells and associated with poorer patient survival, potentially regulated by transcription factors STAT3, ELK3, and EP300. RCRC showed an increased proportion of the CD8-EFFECTOR 3 subpopulation, which co-expresses effector and exhaustion markers, suggesting favorable immunotherapy response. In contrast, the CD4-heat shock proteins (CD4-HSP) subpopulation was almost exclusively present in LCRC, suggesting a potential correlation with a weaker response to immune checkpoint inhibitors. Additionally, APP-CD74 ligand-receptor interactions were significantly enhanced in RCRC, potentially contributing to worse prognosis by inhibiting APP protein cleavage and promoting its accumulation. Validation was performed using an independent single-cell transcriptomic dataset, bulk RNA-seq data from TCGA CRC samples, and qPCR on locally collected CRC tissue specimens. In addition, a spatial transcriptomic dataset of CRC and immunohistochemistry data from the Human Protein Atlas (HPA) database were also used to validate part of the findings. This study provides a comprehensive single-cell transcriptomic atlas highlighting the molecular and cellular disparities between LCRC and RCRC, offering novel insights into tumor biology and informing the development of personalized therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.